Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec;13(6):483-7.
doi: 10.1007/s10147-008-0847-2. Epub 2008 Dec 18.

Chemotherapy for Metastatic Gastric Cancer in Japan


Chemotherapy for Metastatic Gastric Cancer in Japan

Narikazu Boku. Int J Clin Oncol. .


Until the 1990s, there were no chemotherapy regimens with old-generation anticancer agents showing a survival benefit over 5-fluorouracil (FU) alone, and standard chemotherapy for metastatic gastric cancer had not been established. In the late 1990s, several new active agents were developed and some phase III trials with these agents were conducted; the new agent S-1 showed noninferiority to 5-FU in these trials. S-1 plus cisplatin is the first doublet chemotherapy to have shown a survival benefit over monotherapy with S-1. It has been demonstrated that capecitabine and oxaliplatin (OHP) can replace 5-FU and cisplatin (CDDP), offering more convenient treatment options. Thus, combination chemotherapy with an oral fluoropyrimidine (S-1 or capecitabine) and platinum (CDDP or OHP) has been recognized as standard chemotherapy for metastatic gastric cancer all over the world. However, it can be said that none of these new combination chemotherapies have shown remarkable progress from 5-FU plus cisplatin regimens. It is expected that triplet chemotherapy with a taxane; the use of molecular targeting agents; and the establishment of treatment strategies including second line chemotherapy, will lead to remarkable progress in personalized medicine in the near future.

Similar articles

See all similar articles

Cited by 13 articles

See all "Cited by" articles


    1. Jpn J Clin Oncol. 2005 Sep;35(9):520-5 - PubMed
    1. J Clin Oncol. 2006 Nov 1;24(31):4991-7 - PubMed
    1. N Engl J Med. 2008 Jan 3;358(1):36-46 - PubMed
    1. J Clin Oncol. 1992 Apr;10(4):541-8 - PubMed
    1. J Clin Oncol. 2003 Jan 1;21(1):54-9 - PubMed


LinkOut - more resources